<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang S</submitter><funding>National Institute of General Medical Sciences</funding><pagination>20073-20082</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9054207</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(34)</volume><pubmed_abstract>The Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) is a key enzyme in pathways regulating tumor growth signaling, and recently gained interest as a promising anticancer drug target. Many SHP2 inhibitors are currently under development, including SHP099, which has shown potent anticancer activity at low concentrations &lt;i>in vivo&lt;/i>. In this work, we developed multilayer coatings for localized delivery of SHP099 to improve upon current cancer therapies. Layer-by-layer self-assembly was used to develop films composed of chitosan and poly-carboxymethyl-β-cyclodextrin (PβCD) for the delivery of SHP099. SHP099 was successfully loaded into multilayer films &lt;i>via&lt;/i> host-guest interactions with PβCD. Nuclear magnetic resonance spectroscopy confirmed the occurrence of thi</pubmed_abstract><journal>RSC advances</journal><pubmed_title>Controlled delivery of a protein tyrosine phosphatase inhibitor, SHP099, using cyclodextrin-mediated host-guest interactions in polyelectrolyte multilayer films for cancer therapy.</pubmed_title><pmcid>PMC9054207</pmcid><funding_grant_id>U54GM115677</funding_grant_id><pubmed_authors>Yang W</pubmed_authors><pubmed_authors>Antoci V</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>Alkekhia D</pubmed_authors><pubmed_authors>Shukla A</pubmed_authors><pubmed_authors>Battigelli A</pubmed_authors><pubmed_authors>Fairman A</pubmed_authors><pubmed_authors>Moore D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Controlled delivery of a protein tyrosine phosphatase inhibitor, SHP099, using cyclodextrin-mediated host-guest interactions in polyelectrolyte multilayer films for cancer therapy.</name><description>The Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) is a key enzyme in pathways regulating tumor growth signaling, and recently gained interest as a promising anticancer drug target. Many SHP2 inhibitors are currently under development, including SHP099, which has shown potent anticancer activity at low concentrations &lt;i>in vivo&lt;/i>. In this work, we developed multilayer coatings for localized delivery of SHP099 to improve upon current cancer therapies. Layer-by-layer self-assembly was used to develop films composed of chitosan and poly-carboxymethyl-β-cyclodextrin (PβCD) for the delivery of SHP099. SHP099 was successfully loaded into multilayer films &lt;i>via&lt;/i> host-guest interactions with PβCD. Nuclear magnetic resonance spectroscopy confirmed the occurrence of thi</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 May</publication><modification>2025-04-18T14:13:42.261Z</modification><creation>2025-04-04T20:21:56.906Z</creation></dates><accession>S-EPMC9054207</accession><cross_references><pubmed>35520441</pubmed><doi>10.1039/d0ra03864d</doi></cross_references></HashMap>